Small molecule (Molecular glue degrader) · Degrader of Bruton's tyrosine kinase (BTK) · developed by Nurix Therapeutics
Zelebrudomide is an orally bioavailable chimeric targeting molecule that links a cereblon-binding moiety to a BTK-binding moiety. It recruits the CRL4-CRBN E3 ubiquitin ligase to BTK, driving its ubiquitination and proteasomal degradation, and also degrades the CRBN neosubstrates Aiolos and Ikaros. It is being studied in B-cell lymphomas and chronic lymphocytic leukemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04830137 | Phase 1 | Chronic Lymphocytic Leukemia (CLL) | Recruiting | NRIX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Lymphocytic Leukemia (CLL)Diffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)Primary Central Nervous System Lymphoma (PCNSL)Small Lymphocytic Lymphoma (SLL)Waldenstrom Macroglobulinemia (WM)
See NRIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NRIX catalysts and pipeline →